SARS-CoV-2 neutralizing antibody development strategies

Key Findings & Data:Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread.

💡

Conclusion & Impact:This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

🔬Design:Review & Systematic Survey

📍Scope:2019 Verileri

⚙️Variables:Domain Parameters

Abstract

In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targetedtherapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARSCoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

🔖

Cite This Article

TEKİN, Ş., ÖNCÜ, M. D., ÖZTÜRK, H. Ü., KAYA, F., BAHADIR, A. Ö., BALCIOĞLU, B. K., SERHATLI, M., YÜCEL, F., POLAT, H. Ü. (2022). SARS-CoV-2 neutralizing antibody development strategies. Turkish Journal of Biology, Cilt: 44 - Sayı: 3, 203–214. https://ajindex.com/articles/654389

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (9)

Ahmadzadeh V, Farajnia S, Feizi MA, Nejad RA (2014). Antibody humanization methods for development of therapeutic applications. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 33 (2): 67-73.
Akamatsu Y, Pakabunto K, Xu Z, Zhang Y, Tsurushita N (2007). Whole IgG surface display on mammalian cells: application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies. Journal of Immunological Methods 327: 40-52.
Bahadir AO, Balcioglu BK, Uzyol KS, Hatipoglu I, Sogut I et al. (2011). Phage displayed HBV core antigen with immunogenic activity. Applied Biochemistry and Biotechnology 165 (7-8): 1437‐1447. Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R et al. (2006). Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARScoV replication in BALB/c mice. Antiviral Chemistry and Chemotherapy 17: 275-284.
BerryJ D, Jones S, Drebot MA, Andonov A, Sabara M et al. (2004). Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. Journal of Virological Methods 120 (1): 87-96.
Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL et al. (2004). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences of the United States of America 101: 6641-6646.
Casadevall A, Pirofski LA (2020). The convalescent sera option for containing COVID-19. Journal of Clinical Investigation 130 (4): 1545-1548.
Carmen S, Jermutus L (2002). Concepts in antibody phage display. Briefings in Functional Genomics and Proteomics 1 (2): 189‐203. Chen L, Xiong J, Bao L, Shi Y (2020). Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases 20 (4): 398-400.
Chen Z, Zhang L, Qin C, Ba L, Yi CE et al. (2005). Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. Journal of Virology 79: 2678-2688.
Cheong WS, Leow CY, Majeed ABA, Leow CH (2020). Diagnostic and therapeutic potential of shark variable new antigen receptor (VNAR) single domain antibody. International Journal of Biological Macromolecules 147: 369‐375. Davey RT Jr, Dodd L, Proschan MA, Neaton J, Nordwall JN et al. The PREVAIL II Writing Group, for the Multi-National PREVAIL II Study Team (2016). A randomized, controlled trial of